⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 1, 2024Immunity Inflammation and DiseaseOpen Access

Nirmatrelvir and ritonavir combination against COVID‐19 caused by omicron BA.2.2 in the elderly: A single‐center large observational study

Can Chen Ranyi Li Shuliang Xing Lei Cao Yue Qu Qianzhou Lv Xiaoyu Li Zhangzhang Chen

View Full Paper

Ask AI

Bookmark

Share

Abstract

Since coronavirus 2019 (COVID-19) swept the world, a variety of novel therapeutic and prevention strategies have been developed, among which nirmatrelvir-ritonavir is highly recommended. We intended to assess the effectiveness and safety of nirmatrelvir-ritonavir in the elderly mild-to-moderate COVID-19 population caused by the omicron BA.2.2 variant in real-world settings.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chen et al. (2024) studied this question.

synapsesocial.com/papers/68e7115bb6db64358768a3a3 https://doi.org/10.1002/iid3.1232

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Efficacy and Safety of Nirmatrelvir/Ritonavir in Severe Hospitalized Patients with COVID-19 and in Patients at High Risk for Progression to Critical Illness: A Real-World Study2024 · 6 citations
2Nirmatrelvir–Ritonavir Reduced Mortality in Hospitalized Patients with COVID-19 During the Omicron Outbreak: Real-World Evidence from Beijing2024 · 5 citations
3Associations of nirmatrelvir-ritonavir treatment with death and clinical improvement in hospitalized patients with COVID-19 during the Omicron wave in Beijing, China: a multicentre, retrospective cohort study2024 · 6 citations
4Clinical real-world effectiveness of nirmatrelvir/ritonavir for the treatment of SARS-CoV-2 infection: A meta-analysis2024
55PSQ-051 Effectiveness and safety of nirmatrelvir/ritonavir in older patients at a nursing home with COVID-192024